Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Change in Inventory: 2015-2025

Historic Change in Inventory for Aytu Biopharma (AYTU) over the last 11 years, with Sep 2025 value amounting to -$1.1 million.

  • Aytu Biopharma's Change in Inventory fell 216.17% to -$1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.1 million, marking a year-over-year decrease of 132.80%. This contributed to the annual value of -$382,000 for FY2025, which is 107.92% down from last year.
  • Latest data reveals that Aytu Biopharma reported Change in Inventory of -$1.1 million as of Q3 2025, which was down 303.86% from $518,000 recorded in Q2 2025.
  • In the past 5 years, Aytu Biopharma's Change in Inventory registered a high of $2.1 million during Q3 2022, and its lowest value of -$7.2 million during Q2 2021.
  • In the last 3 years, Aytu Biopharma's Change in Inventory had a median value of $622,000 in 2023 and averaged $428,273.
  • Per our database at Business Quant, Aytu Biopharma's Change in Inventory spiked by 1,082.02% in 2022 and then crashed by 216.17% in 2025.
  • Over the past 5 years, Aytu Biopharma's Change in Inventory (Quarterly) stood at $390,000 in 2021, then plummeted by 79.74% to $79,000 in 2022, then surged by 765.82% to $684,000 in 2023, then slumped by 191.67% to -$627,000 in 2024, then plummeted by 216.17% to -$1.1 million in 2025.
  • Its Change in Inventory stands at -$1.1 million for Q3 2025, versus $518,000 for Q2 2025 and $61,000 for Q1 2025.